Last reviewed · How we verify

NCT05567978: LYNX

Comparison of 2 Pupillometric Indices in Cerebral Brain Patients

Completed Last updated 19 February 2025
What this trial tests

trial testing pupillometry index in Pupillometry Index in Brain Lesion in 100 participants. Completed in 31 December 2024.

Timeline
31 October 2022
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date31 October 2022
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Pupillometry Index in Brain Lesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pupillary examination, and in particular pupillary reactivity to light, is fundamental to the monitoring and follow-up in intensive care units of patients with acute brain injury. A pupillometric index combining different parameters of pupillary light reflex has been described as predictive of intracranial hypertension and the neurological outcome of the patient.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05567978.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing